

**Lawler, Mark**

European Cancer Organisation



Mark has published over 180 papers in international peer review journals, including key papers in the highest impact journals ([New Engl J Medicine](#), [Lancet](#), [Nature Medicine](#), [Lancet Oncology](#), [Cancer Discovery](#), [Nature Comms](#), [Gut](#) etc). He has been successful in attracting over £20M of research funding. He is a member of the Board of the **European Alliance for Personalised Medicine** (EAPM) and developed EAPM's research strategy. Mark's work has been recognised by a number of national/international awards including the [Vander Molen Prize for Leukaemia Research](#), the [Ely Lilly Prize](#), the [St Lukes Medal for Cancer Research](#) and the [Graves Medal for Medical Research](#).

Mark is Associate Director of **Health Data Research Wales-Northern Ireland**, one of only 6 substantive sites of Health Data Research UK(HDR-UK), which aims to drive innovative precision medicine and public health approaches through the use of Big Data. He is also national lead for the Cancer Data Research Strategy for HDR-UK. In the wake of the Cambridge Analytica/Facebook scandal, he recently led a pan European group in the publication of a roadmap to restore public trust in health data, published in [Lancet Oncology](#), the premier cancer journal in the world. Mark was co-chair of the Cancer Task Team of the Clinical Working Group of the **Global Alliance for Genomics and Health**, an international cooperative dedicated to effective and responsible sharing of genomic and clinical data. He has authored a number of key papers including a blueprint for cancer data sharing ([Nature Medicine](#)) and a road map/call to action for a Global Cancer Knowledge Network in the [New England Journal of Medicine](#), the top medical journal in the world. He is co-lead of an ambitious proposal to develop a Global Innovation Institute which will include the One Health Innovation Centre (OHIC), Europe's first Health and Agri-Food Informatics Innovation Centre.

Mark is the Queen's Lead of the £5M Medical Research Council-Cancer Research UK funded Personalised medicine programme **Stratified Medicine in Colorectal Cancer Consortium** (S:CORT), a UK-wide consortium investigating novel precision medicine approaches in

CRC. His international reputation in CRC was instrumental in his leading a Critical Gaps in CRC Research Initiative, recently published in the high impact factor journal [Gut](#); this landmark publication has attracted significant global attention (his podcast had the most “hits” of any article in the journal).

Mark is frequently invited as a guest speaker to international conferences and sits on a number of high level boards/committees at European level including EAPM, the Scientific Board of the European Cancer Patient Coalition and the European Cancer Organisation (ECCO) Oncopolicy Forum

Mark has a strong commitment to patient-centred research/care and to addressing cancer inequalities. He was the architect of the **European Cancer Patient's Bill of Rights (BoR)**, a catalyst for change and empowerment tool for cancer patients which he launched in the European Parliament on World Cancer Day 2014. The BoR has been adopted across Europe and led to the **70:35 Vision**, 70% survival for all cancer patients in Europe by 2035 which was recently adopted by ECCO, the largest interdisciplinary cancer organisation in Europe. Mark's advocacy work was instrumental in the recent decision to recommend that boys be included in the national UK HPV vaccination programme. He is also committed to the provision of optimal pathology and laboratory medicine for citizens in resource-limited settings and was senior author of a recent paper in [The Lancet](#) as part of [The Lancet Series on Pathology and Laboratory Medicine in Low- and Middle-Income Countries](#).

(last updated 28.09.2018)